HALO Halozyme Therapeutics, Inc.

NASDAQ
$96.50

Halozyme Therapeutics, Inc. (HALO) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is $2.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -17.5% since its last earnings release on November 5, 2026.

Halozyme Therapeutics Beat Expectations, Raises Guidance In-line with Estimates
Thursday, November 5, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:05 PM ET
Earnings Whisper
-
vs $2.52 (GAAP)
Rev est $548.53M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $101.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.